FR15C0085I2 - Expression optimisee de hpv 52 l1 dans une levure - Google Patents

Expression optimisee de hpv 52 l1 dans une levure

Info

Publication number
FR15C0085I2
FR15C0085I2 FR15C0085C FR15C0085C FR15C0085I2 FR 15C0085 I2 FR15C0085 I2 FR 15C0085I2 FR 15C0085 C FR15C0085 C FR 15C0085C FR 15C0085 C FR15C0085 C FR 15C0085C FR 15C0085 I2 FR15C0085 I2 FR 15C0085I2
Authority
FR
France
Prior art keywords
hpv
yeast
optimized expression
optimized
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR15C0085C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of FR15C0085I1 publication Critical patent/FR15C0085I1/fr
Application granted granted Critical
Publication of FR15C0085I2 publication Critical patent/FR15C0085I2/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/025Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/045Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR15C0085C 2004-03-24 2015-12-04 Expression optimisee de hpv 52 l1 dans une levure Active FR15C0085I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55592604P 2004-03-24 2004-03-24
PCT/US2005/009199 WO2005097821A1 (en) 2004-03-24 2005-03-18 Optimized expression of hpv 52 l1 in yeast
EP05725933A EP1730175B1 (en) 2004-03-24 2005-03-18 Optimized expression of hpv 52 l1 in yeast

Publications (2)

Publication Number Publication Date
FR15C0085I1 FR15C0085I1 (enrdf_load_stackoverflow) 2016-08-01
FR15C0085I2 true FR15C0085I2 (fr) 2016-11-25

Family

ID=34964085

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0085C Active FR15C0085I2 (fr) 2004-03-24 2015-12-04 Expression optimisee de hpv 52 l1 dans une levure

Country Status (31)

Country Link
US (2) US7700103B2 (enrdf_load_stackoverflow)
EP (1) EP1730175B1 (enrdf_load_stackoverflow)
JP (1) JP4833962B2 (enrdf_load_stackoverflow)
KR (1) KR101203403B1 (enrdf_load_stackoverflow)
CN (1) CN1934131B (enrdf_load_stackoverflow)
AR (1) AR048191A1 (enrdf_load_stackoverflow)
AT (1) ATE466022T1 (enrdf_load_stackoverflow)
AU (1) AU2005230907C1 (enrdf_load_stackoverflow)
BE (1) BE2015C066I2 (enrdf_load_stackoverflow)
BR (1) BRPI0509079B8 (enrdf_load_stackoverflow)
CA (1) CA2560487C (enrdf_load_stackoverflow)
CY (2) CY1110349T1 (enrdf_load_stackoverflow)
DE (1) DE602005020913D1 (enrdf_load_stackoverflow)
DK (1) DK1730175T3 (enrdf_load_stackoverflow)
ES (1) ES2343255T3 (enrdf_load_stackoverflow)
FR (1) FR15C0085I2 (enrdf_load_stackoverflow)
HU (1) HUS1500062I1 (enrdf_load_stackoverflow)
IL (1) IL178140A (enrdf_load_stackoverflow)
LT (2) LTPA2015050I1 (enrdf_load_stackoverflow)
LU (1) LU92903I2 (enrdf_load_stackoverflow)
MY (1) MY148656A (enrdf_load_stackoverflow)
NL (1) NL300777I1 (enrdf_load_stackoverflow)
NO (3) NO338055B1 (enrdf_load_stackoverflow)
NZ (1) NZ549898A (enrdf_load_stackoverflow)
PL (1) PL1730175T3 (enrdf_load_stackoverflow)
PT (1) PT1730175E (enrdf_load_stackoverflow)
RU (1) RU2373219C2 (enrdf_load_stackoverflow)
SI (1) SI1730175T1 (enrdf_load_stackoverflow)
TW (1) TWI349036B (enrdf_load_stackoverflow)
WO (1) WO2005097821A1 (enrdf_load_stackoverflow)
ZA (1) ZA200607575B (enrdf_load_stackoverflow)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
CN1869215B (zh) * 2006-05-19 2012-07-04 长春百克生物科技股份公司 一种制备人乳头瘤病毒的病毒样颗粒的方法
AU2008226974B2 (en) 2007-03-09 2013-08-15 Merck Sharp & Dohme Llc Papillomavirus vaccine compositions
CN101440371B (zh) * 2007-11-23 2012-09-05 上海泽润生物科技有限公司 一种16型人乳头状瘤病毒主要衣壳蛋白l1基因
EP2223933B1 (en) * 2007-11-23 2016-01-27 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein l1 of human papilloma viruses
SI2569009T1 (sl) * 2010-05-14 2020-02-28 Baxalta Incorporated Himere OSPA in njihova uporaba v cepivih
WO2011149897A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
IN2013CN00536A (enrdf_load_stackoverflow) 2010-07-02 2015-07-03 Univ Xiamen
US8361720B2 (en) * 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
EP2646559A2 (en) 2010-12-03 2013-10-09 MS Technologies, LLC Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
RU2445358C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18
RU2445357C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16
CN110484554B (zh) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN104164374B (zh) * 2013-05-17 2019-10-22 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
EP3057612B1 (en) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
CN104878022A (zh) * 2015-04-27 2015-09-02 段青姣 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用
CN106701796B (zh) * 2015-08-12 2021-11-16 北京康乐卫士生物技术股份有限公司 52型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750049B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒52亚型蛋白表达
IL295234A (en) 2020-02-14 2022-10-01 Merck Sharp & Dohme Llc Hpv vaccine
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113549634B (zh) * 2021-06-07 2023-03-31 郑州大学 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
AR126708A1 (es) 2021-08-06 2023-11-08 Merck Sharp & Dohme Llc Vacuna para el vph
CN118019547A (zh) 2021-08-19 2024-05-10 默沙东有限责任公司 热稳定脂质纳米粒子及其使用方法
TW202513091A (zh) 2023-06-09 2025-04-01 美商默沙東有限責任公司 用於人類乳突病毒疫苗之奈米乳液佐劑組合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339729C (en) * 1988-10-26 1998-03-17 Wayne D. Lancaster Human papillomavirus type 52 dna sequences and methods for employing thesame
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
DK0969862T3 (da) 1997-02-07 2007-02-12 Merck & Co Inc Syntetisk HIV gag-gener
JP4434479B2 (ja) 1997-07-09 2010-03-17 ザ・ユニバーシティ・オブ・クイーンズランド 標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法
WO2000009157A1 (en) 1998-08-14 2000-02-24 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
DK1105466T3 (da) * 1998-08-14 2006-08-14 Merck & Co Inc Fremgangsmåde til oprensning af humant papillomvirus-viruslignende partikler
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
ES2233437T3 (es) * 1999-08-25 2005-06-16 MERCK & CO., INC. Genes sinteticos del papilomavirus optimizados para expresion en celulas humanas.
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
CN1262665C (zh) 2000-07-21 2006-07-05 葛兰素集团有限公司 经过密码子最优化的乳头状瘤病毒序列
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
WO2004084831A2 (en) * 2003-03-24 2004-10-07 Merck & Co. Inc. Optimized expression of hpv 31 l1 in yeast
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast

Also Published As

Publication number Publication date
US7700103B2 (en) 2010-04-20
LTC1730175I2 (lt) 2017-05-10
LTPA2015050I1 (lt) 2016-01-11
ATE466022T1 (de) 2010-05-15
NZ549898A (en) 2009-06-26
MY148656A (en) 2013-05-15
NO2022050I1 (no) 2022-11-30
EP1730175B1 (en) 2010-04-28
AR048191A1 (es) 2006-04-05
BRPI0509079B8 (pt) 2021-07-06
CN1934131A (zh) 2007-03-21
TW200602490A (en) 2006-01-16
BE2015C066I2 (enrdf_load_stackoverflow) 2024-08-08
CA2560487C (en) 2013-01-29
NO2017005I1 (no) 2017-01-20
NL300777I2 (enrdf_load_stackoverflow) 2015-12-29
US20080226660A1 (en) 2008-09-18
TWI349036B (en) 2011-09-21
US20100035818A1 (en) 2010-02-11
ES2343255T3 (es) 2010-07-27
NL300777I1 (enrdf_load_stackoverflow) 2015-12-29
BRPI0509079A (pt) 2007-08-21
PL1730175T3 (pl) 2010-09-30
RU2006137363A (ru) 2008-04-27
CN1934131B (zh) 2010-12-29
CY2015052I2 (el) 2016-06-22
RU2373219C2 (ru) 2009-11-20
LU92903I2 (fr) 2016-03-08
IL178140A0 (en) 2006-12-31
AU2005230907B2 (en) 2011-05-19
KR101203403B1 (ko) 2012-11-21
IL178140A (en) 2010-11-30
CA2560487A1 (en) 2005-10-20
AU2005230907A1 (en) 2005-10-20
EP1730175A1 (en) 2006-12-13
ZA200607575B (en) 2008-08-27
FR15C0085I1 (enrdf_load_stackoverflow) 2016-08-01
AU2005230907C1 (en) 2016-07-28
NO20064815L (no) 2006-10-23
WO2005097821A1 (en) 2005-10-20
KR20060134120A (ko) 2006-12-27
BRPI0509079B1 (pt) 2020-05-19
US7744892B2 (en) 2010-06-29
JP2007530040A (ja) 2007-11-01
HUS1500062I1 (hu) 2017-07-28
PT1730175E (pt) 2010-06-25
CY2015052I1 (el) 2016-06-22
DE602005020913D1 (de) 2010-06-10
CY1110349T1 (el) 2015-04-29
JP4833962B2 (ja) 2011-12-07
SI1730175T1 (sl) 2010-08-31
DK1730175T3 (da) 2010-08-23
NO338055B1 (no) 2016-07-25

Similar Documents

Publication Publication Date Title
FR15C0085I2 (fr) Expression optimisee de hpv 52 l1 dans une levure
FR15C0081I2 (fr) Expression optimisee de hpv 58 l1 dans de la levure
FR15C0083I2 (fr) Expression optimisee de hpv45 l1 dans la levure
EP1958151A4 (en) IMAGE IMPROVEMENT IN THE MOSAIC DOMAIN
DE602005020229D1 (de) Schaufel mit prallgekühltem Übergang von grossem Krümmungsradius
DE602005011932D1 (de) Mosaik-anzeige
FR2891289B1 (fr) Panneau composite pour toitures et constructions similaires
FR2842105B1 (fr) Localisation des genes impliques dans la canitie precoce
FR2842104B1 (fr) Genes impliques dans la canitie precoce
FR2876401B1 (fr) Panneau muni d'une toile metallique
FR2900691B3 (fr) Ensemble d'activation dans une pompe
AU2004903109A0 (en) Developments Relating to Tents
ITMI20041152A1 (it) Struttura di slitta
ITAP20040002A1 (it) Integrazione ciclo computer e visualizzazione completa dei parametri di conduzione veicolo.